Sarah Reinke
Overview
Explore the profile of Sarah Reinke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seifert N, Reinke S, Grund J, Muller-Meinhard B, Richter J, Heilmann T, et al.
Leukemia
. 2024 Dec;
39(3):684-693.
PMID: 39690183
The Tumor Microenvironment (TME) in classical Hodgkin Lymphoma (HL) contains abundant immune cells and only few neoplastic Hodgkin and Reed-Sternberg cells (HRSC). We analyzed the T-cell receptor (TCR) repertoire to...
2.
Heger J, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmuller J, et al.
J Clin Oncol
. 2024 Sep;
42(35):4218-4230.
PMID: 39348625
Purpose: Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical risk factors lack discriminatory power, intensity of therapy is mainly...
3.
Muller-Meinhard B, Seifert N, Grund J, Reinke S, Yalcin F, Kaul H, et al.
Hemasphere
. 2024 Jun;
8(6):e84.
PMID: 38836098
Hodgkin-Reed-Sternberg cells (HRSCs) in classic Hodgkin Lymphoma (HL) frequently lack expression of human leukocyte antigen class I (HLA-I), considered to hamper activation of cytotoxic T cells in the tumor microenvironment...
4.
Grund J, Iben K, Reinke S, Buhnen I, Plutschow A, Muller-Meinhard B, et al.
Br J Haematol
. 2023 Mar;
201(6):1097-1102.
PMID: 36921595
B-cell content in the tumour microenvironment (TME) of classic Hodgkin lymphoma (HL) is known to be associated with prognosis. Here we demonstrate that whole slide image analysis using routinely available...
5.
Au-Yeung R, Arias Padilla L, Zimmermann M, Reinke S, Oschlies I, Escherich G, et al.
Leukemia
. 2022 Nov;
37(2):488-491.
PMID: 36352192
No abstract available.
6.
Iaccarino I, Mourtada F, Reinke S, Patil P, Doose G, Monaco G, et al.
Noncoding RNA
. 2022 Jun;
8(3).
PMID: 35736637
Successful immunotherapy in both solid tumors and in hematological malignancies relies on the ability of T lymphocytes to infiltrate the cancer tissue and mount an immune response against the tumor....
7.
Sobesky S, Mammadova L, Cirillo M, Drees E, Mattlener J, Dorr H, et al.
Med
. 2022 May;
2(10):1171-1193.e11.
PMID: 35590205
Background: Individualization of treatment in Hodgkin's lymphoma is necessary to improve cure rates and reduce treatment side effects. Currently, it is hindered by a lack of genomic characterization and sensitive...
8.
Garcia-Marquez M, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, et al.
Leukemia
. 2021 Sep;
36(3):760-771.
PMID: 34584203
While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1) antibodies, the exact modes of action remain controversial. To elucidate the circulating lymphocyte phenotype and systemic...
9.
Gerhard-Hartmann E, Goergen H, Brockelmann P, Mottok A, Steinmuller T, Grund J, et al.
Br J Haematol
. 2021 Sep;
196(1):116-126.
PMID: 34520052
High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed-Sternberg cells (HRSC) have been shown...
10.
Reinke S, Brockelmann P, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F, et al.
Blood
. 2020 Oct;
136(25):2851-2863.
PMID: 33113552
Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to antibodies targeting programmed cell death protein 1 (PD1) and is characterized by scarce Hodgkin and Reed-Sternberg cells (HRSCs), perpetuating...